Literature DB >> 8902545

Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats.

P Simon1, C Hémet, J Costentin.   

Abstract

Locomotor effects of modafinil were analysed and compared in various strains of mice and rats. A stimulation of locomotor activity was evidenced in all tested strains of mice: Swiss CD1, BALB/c, DBA2, C3H, B6CBAF1/JICO, Nude CD1 and in all tested strains of rats: Long Evans, Sprague Dawley, Wistar. In mice, from 10 mg/kg intraperitoneal, a precocious stimulant effect was observed. The drug seems to operate in its native form on the mouse brain since its intracerebroventricular administration (from 15 micrograms/mouse) elicited a stimulation of locomotion. In rats, the effective doses were higher (from 40 mg/kg ip); the effects of modafinil mainly oppose to the decrease in locomotion (habituation) which normally occurs in control animals. In addition, it was observed that administration of modafinil in rats habituated to their environment induced a recovery of locomotor activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902545     DOI: 10.1111/j.1472-8206.1996.tb00597.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  10 in total

1.  Stress modulation of the memory retrograde-enhancing effects of the awakening drug modafinil in mice.

Authors:  Daniel Béracochéa; Pierrette Liscia; Christophe Tronche; Frédéric Chauveau; Jean-Claude Jouanin; Christophe Piérard
Journal:  Psychopharmacology (Berl)       Date:  2007-10-13       Impact factor: 4.530

2.  Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse.

Authors:  Carmela M Reichel; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

Review 3.  Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.

Authors:  Gillian M Keating; Michael J Raffin
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

Authors:  K J McClellan; C M Spencer
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

5.  Preclinical evaluation of the abuse potential of Pitolisant, a histamine H₃ receptor inverse agonist/antagonist compared with Modafinil.

Authors:  M Uguen; D Perrin; S Belliard; X Ligneau; P M Beardsley; J M Lecomte; J C Schwartz
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

6.  Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction.

Authors:  Tristan Shuman; Denise J Cai; Jennifer R Sage; Stephan G Anagnostaras
Journal:  Behav Brain Res       Date:  2012-08-03       Impact factor: 3.332

Review 7.  Psychostimulants and cognition: a continuum of behavioral and cognitive activation.

Authors:  Suzanne Wood; Jennifer R Sage; Tristan Shuman; Stephan G Anagnostaras
Journal:  Pharmacol Rev       Date:  2013-12-16       Impact factor: 25.468

8.  Oral dosing of rodents using a palatable tablet.

Authors:  Sandeep S Dhawan; Shuang Xia; David S Tait; Christoffer Bundgaard; Ellen Bowman; Verity J Brown
Journal:  Psychopharmacology (Berl)       Date:  2018-03-06       Impact factor: 4.530

9.  Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.

Authors:  Stéphane Krief; Isabelle Berrebi-Bertrand; Isabelle Nagmar; Martin Giret; Simon Belliard; David Perrin; Marilyne Uguen; Philippe Robert; Jeanne-Marie Lecomte; Jean-Charles Schwartz; Olivier Finance; Xavier Ligneau
Journal:  Pharmacol Res Perspect       Date:  2021-10

10.  Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination.

Authors:  Dominique Vodovar; Adeline Duchêne; Catriona Wimberley; Claire Leroy; Géraldine Pottier; Yves Dauvilliers; Christian Giaume; Jian-Sheng Lin; Franck Mouthon; Nicolas Tournier; Mathieu Charvériat
Journal:  Int J Neuropsychopharmacol       Date:  2018-07-01       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.